Marek’s disease vaccine activates chicken macrophages

Dan Wang¹, Shuhong Sun¹, Mohammad Heidari²,*

¹College of Animal Science and Veterinary Medicine, Shandong Agricultural University, Tai’an 271018, China
²Avian Disease and Oncology Laboratory, U.S. Department of Agriculture, Agriculture Research Service (USDA-ARS), East Lansing, MI 48823, USA

To provide insights into the role of innate immune responses in vaccine-mediated protection, we investigated the effect of Marek’s disease (MD) vaccine, CVI988/Rispens, on the expression patterns of selected genes associated with activation of macrophages in MD-resistant and MD-susceptible chicken lines. Upregulation of interferon γ, interleukin (IL)-1β, IL-8, and IL-12 at different days post-inoculation (dpi) revealed activation of macrophages in both chicken lines. A strong immune response was induced in cecal tonsils of the susceptible line at 5 dpi. The highest transcriptional activities were observed in spleen tissues of the resistant line at 3 dpi. No increase in the population of CD3+ T cells was observed in duodenum of vaccinated birds at 5 dpi indicating a lack of involvement of the adaptive immune system in the transcriptional profiling of the tested genes. There was, however, an increase in the number of macrophages in the duodenum of vaccinated birds. The CVI988/Rispens antigen was detected in the duodenum and cecal tonsils of the susceptible line at 5 dpi but not in the resistant line. This study sheds light on the role of macrophages in vaccine-mediated protection against MD and on the possible development of new recombinant vaccines with enhanced innate immune system activation properties.

Keywords: CVI988/Rispens, Marek’s disease, cecal tonsils, duodenum, macrophages

Introduction

Marek’s disease virus (MDV), a highly cell-associated oncogenic α-herpesvirus, is the etiological agent of Marek’s disease (MD), a contagious lymphoproliferative disease of domestic chickens [10]. MDV causes immunosuppression, neurological disorders, chronic wasting, blindness, and fatal T cell lymphomas in susceptible chickens [11]. The early pathogenesis of MD is associated with an initial lytic infection of B cells followed by latent infection of activated CD4+ T cells that leads to the destruction of B and T cells, atrophy of bursa of Fabricius and thymus, and transient immunosuppression [7]. The last phase of MDV infection is characterized by reactivation of the virus with the second cycle of lytic infection, induction of T cell lymphomas, and permanent immunosuppression [32]. The MDV-induced immunosuppression increases the susceptibility of infected birds to other diseases such as chicken anemia virus, reovirus, and infectious bursal disease virus [3]. It is believed that latently infected T cells migrate through the bloodstream and establish lymphomas in the visceral organs, peripheral nerves, and skin [7]. Fully infectious enveloped cell-free virions are produced in feather follicle epithelial cells (FFE) and eventually released into the environment with molted feathers and dander to infect contact birds [8].

MDV strains have been categorized into three serotypes based on antigenic differences and biological features. Oncogenic strains, including their attenuated forms, are classified as serotype 1, while non-oncogenic strains isolated from chickens and turkeys are classified as serotypes 2 and 3, respectively [11,19]. The attenuated serotype 1 CVI988/Rispens and the non-oncogenic serotypes 2 and 3 (SB-1 and HTV, respectively) have been used as vaccines to prevent and control MD [26,29,33]. The naturally attenuated serotype 1 CVI988/Rispens, which was first described by Rispens et al. [30], is a commercial vaccine and is considered the gold standard against highly pathogenic (very virulent and very virulent plus) MDV pathotypes [12,29]. The attenuated serotype 1 viruses, used as vaccines, provide better protection and induce more effective immune responses, probably due to antigenic similarity with pathogenic strains of MDV [36]. The live MD vaccines prevent transient paralysis and lymphoma formation and mediate significant reductions in viral replication and assembly in FFE. They do not, however, prevent host infection, viral replication, and shedding [8].
Although MD vaccines have been in use for more than four decades, the specific mechanism of vaccine-induced protection is unclear. It has been shown that innate immune responses are induced but, unlike most other vaccines, adaptive immune system activation in response to MD vaccine is minimal [22]. Macrophages are essential cellular components of the innate immune defense system that have an essential role in shaping the adaptive immune system. Activated macrophages can greatly influence immune responses to viral infection and are able to spread through the production of several cytokines and chemokines including interleukin (IL)-1β, IL-6, IL-8, IL-12, interferons (IFNs), and tumor necrosis factor [1,28]. Studies have shown that macrophages play an important role in controlling initial MDV replication and the destruction of viral antigens [13,14,39]. In vitro and in vivo studies have indicated that macrophages play a pivotal role in the pathogenesis of MD. Macrophages obtained from MDV-infected chickens can inhibit MDV replication in vitro much more efficiently than macrophages from control birds [16]. Macrophages from MD-susceptible line 72 have greater antiviral activities than macrophages of MD-resistant line 63 [27]. Although the mechanism of inhibition of MDV replication has not been fully described, it has been postulated that IFNs and macrophage activating factor may have essential roles [37]. While NO induces a direct inhibitory effect on viral replication and infection, other mediators released by activated macrophages regulate natural killer (NK) cell activation and IFN-γ production, leading to a positive feedback that increases the activation of both cell types within tissues and, ultimately, an effective innate immune response [5,14,25,32]. NK cell-derived IFN-γ inhibits viral replication, induces Th1-type immunity, and activates macrophages [17,18].

In contrast to the amount of information on macrophage responses to MDV infection, there is a paucity of reports concerning the role of macrophages in MD vaccine-induced immunity. The purpose of the present study was to investigate the role of macrophages in CVI988/Rispens-mediated protection in MD-susceptible and MD-resistant chicken lines.

Materials and Methods

Experimental chickens

The specific-pathogen-free (SPF) chickens in the current study were from progenitor line 63 (MD-resistant) and 72 (MD-susceptible) birds [2]. These birds were from unvaccinated breeder hens and lacked antibodies to many avian pathogens including MDV, herpesvirus of turkey, reticuloendotheliosis virus and avian leukosis virus. The chicks were hatched and raised under SPF conditions at the Avian Disease and Oncology Laboratory (ADOL) poultry facility and housed in modified Horsfall-Bauer isolation units for the duration of the experiment. All animal experiments were approved and carried out in accordance with the guidelines set forth by the ADOL Institutional Animal Care and Use Committee (approval No. AADOL ACUC 15.15) and the Guidelines for Care and Use of Laboratory Animals published by Institute for Laboratory Animal Research in 1996.

Experiment design

One-day-old chicks from each line were randomly distributed into two groups of 15 birds each and kept in separate isolators. Birds from one group of each chicken line were vaccinated with CVI988/Rispens at post-hatch day 12, while the second group of each line served as the negative control. Three chickens from each group were euthanatized by CO₂ inhalation and necropsied for tissue collection at 3, 5, and 10 days post-immunization (dpi). A portion of each duodenum and cecal tonsil (CT) was stored in RNAlater (Ambion, USA) to prevent RNA degradation. A small sample of each duodenum and CT was also put in optimal cutting temperature compound (Sakura Finetek USA, USA), snap-frozen in liquid nitrogen, and stored at –80°C until used for immunohistochemical analysis. At 3 and 5 dpi, spleen tissues were aseptically removed and stored in Liebowitz-McCoy (LM) medium for macrophage isolation shortly after collection.

Vaccination

The CVI988/Rispens vaccine was purchased from Intervet (USA). Chickens were inoculated intraperitoneally with 2,000 plaque-forming unit (PFU) of the vaccine virus at day 12 post-hatch per manufacturer’s instruction. One dose of vaccine contains approximately 2,000 PFU of the vaccine virus.

Spleen macrophage isolation

Pools of spleens from three vaccinated and three non-vaccinated chickens were decapsulated and gently passed through a size 60-mesh screen (Sigma-Aldrich, USA) to obtain a single-cell suspension. Splenocytes were re-suspended in cold LM medium (5% fetal bovine serum), harvested after centrifugation on a Histopaque-1077 (Sigma-Aldrich) at 700 × g for 30 min at room temperature to move dead cells and, then, washed twice in cold phosphate buffered saline (PBS). The pellet was re-suspended in cold degassed buffer (PBS, 0.5% bovine serum albumin, 2 mM EDTA, pH 7.2), and the number of cells was determined by using a TC-10 automated cell counter (Bio-Rad Laboratories, USA). Then, the cells were labeled with mouse monoclonal antibody KUL-01 (SouthernBiotech, USA) to identify chicken macrophages and monocytes [23,24,35], according to the manufacturer’s recommendations. MicroBeads coated with goat anti-mouse IgG1 (Miltenyi Biotec, USA) were used for separation of macrophages from the mixed splenocytes according to the manufacturer’s recommendations. An LS column and a MACS Separator (Miltenyi Biotec) were used to collect macrophages.
according to the total number of live cells and the number of magnetically labeled cells. Macrophages were suspended with TRIZol (Invitrogen, USA) and stored at −80°C for RNA isolation. To prevent unwanted activation of macrophages in vitro, spleen tissues were kept on ice and ice-cold solutions were used for separation of macrophages.

**RNA isolation**

Total RNA was isolated from the homogenized duodenum and CT tissues or isolated spleen macrophages of three birds of each group (see Experiment design) at days 3, 5, and 10 dpi; (three biological replications) by using Tri Reagent RT (Molecular Research Center, USA) according to the manufacturer’s instructions.

**Real-time polymerase chain reaction**

Real-time polymerase chain reaction (PCR) analysis for relative quantification of chicken gene expression transcripts was carried out at the Research Technology and Support Facility of Michigan State University in East Lansing, Michigan, USA. Each reaction mix (10 μL) was prepared by adding 5 μL SYBR Green PCR master mix (2×; Applied Biosystems, USA), 2.5 μL of 1:20 dilution of cDNA template (corresponding to 2 μg of the starting amount of RNA), and 2.5 μL each of the specific primers (25 μM). The amplification reactions were carried out at 50°C for 2 min, 95°C for 10 min, 40 cycles at 95°C for 15 sec followed by 57°C for 1 min. All reactions were run in three biologic replications in a 7900HT Sequence Detection System (Applied Biosystems). The primers for chicken genes were designed by using MacVector software (ver. 14.5.3; Accelrys, USA), and all the primers were synthesized by MWG Biotech (USA). The primers sequences and their amplicons are listed in Table 1 [40]. The housekeeping gene β-actin was included in the assay to ensure that similar amounts of cDNA were used in each reaction and that a uniform amplification process was obtained.

### Table 1. Primer sets used for chicken gene expression analysis

| Gene | Forward primers | Reverse primers | Length (bp) | Reference |
|------|-----------------|-----------------|-------------|-----------|
| β-Actin | 5′-CCCACCTGAGCGCAAGTACT-3′ | 5′-AAGCATTTGCGGTGGACAAT-3′ | 132 | [40] |
| IFN-α | 5′-TACCGCATCTGCTGCTCAAC-3′ | 5′-AGAGAAGGTGGCCTCCTGGG-3′ | 93 | [40] |
| IFN-γ | 5′-AAGTCGAAAGCOCGACATCAAAC-3′ | 5′-CTGGATTCTCAAGTCGTTCATCG-3′ | 132 | [40] |
| IL-1β | 5′-ATGACCAAAATCTGCTGGGAG-3′ | 5′-AGGTACGGCGGTCAAAACC-3′ | 91 | [40] |
| IL-6 | 5′-GACGAGGAGAAATGCTGAC-3′ | 5′-CCGAGTCTGGGATGACCATTTC-3′ | 190 | [40] |
| IL-8 | 5′-TAAAGATTGGGGAATGAGCT-3′ | 5′-TTCACATTTCTGAGTCG-3′ | 120 | [40] |
| IL-12 | 5′-CTGGAAACTGCCCCGTACTG-3′ | 5′-GGTCTGCAATGTGTAAC-3′ | 150 | [40] |

IFN, interferon; IL, interleukin.

**Immunohistochemistry**

The frozen tissue samples, embedded in optimal cutting temperature, were sectioned at 5 microns, placed on 2% 3-aminopropyltriethoxysilane-coated slides, and air dried overnight. The microtome sections were fixed in formal acetate fixative at room temperature for 10 min and then rinsed three times in Tris-buffered saline for 5 min each. To block the endogenous peroxidase activity, the samples were treated with 0.3% hydrogen peroxide in Tris-buffered saline for 20 min followed by rinses with tap and distilled water. All of the avidin-biotin-complex staining steps were performed at room temperature by using a DAKO Autostainer (Agilent Technologies, USA) followed by rinses in Tris-buffered saline with Tween 20 (Scytek Laboratories, USA). Non-specific proteins were blocked with normal horse serum diluted in PBS (1/30 dilution; Vector Laboratories, USA) for 30 min. Sections were then incubated with an avidin-biotin blocking system for 15 min each (Avidin D [Vector Laboratories] and d-Biotin [Sigma-Aldrich]). For detection of specific immune cells, tissue samples were incubated with mouse anti-chicken macrophage or CD3+ T cell monoclonal antibodies at working dilutions of 1:200 (KUL01 and CT-3, respectively; SouthernBiotech) for 1 h in normal antibody diluent (NAD; Scytek Laboratories). Samples were rinsed and then incubated with biotinylated horse anti-mouse IgG (H + L) prepared at 11.5 μg/mL in NAD and incubated for 60 min. For detection of CVI988/Rispens antigen, mouse anti-gB monoclonal antibody developed at the ADOL poultry facility was used [19] at a 1:1,000 working dilution. Samples then were further treated with ready to use (R.T.U.) Vector Elite Peroxidase Reagent (Vector Laboratories) for 30 min. Finally, the tissues were incubated with Vector NovaRED peroxidase chromogen (Vector Laboratories) for reaction development for 15 min, followed by counterstaining in Gill hematoxylin (Thermo Fisher, USA) for 15 sec.

**Statistical analysis**

Relative quantification of chicken gene expression was...
determined using a \(2^{-\Delta \text{CT}}\) method [21]. The level of expression of the target genes (IL-1\(\beta\), IL-6, IL-8, IL-12, IFN-\(\alpha\), IFN-\(\gamma\)) in CT, duodenum, and spleen macrophages of age- and line-matched control birds were used as references or baselines for calculation of fold changes in gene expression in the CVI988/Rispens-vaccinated chickens of each line. The expression of each gene was normalized to the expression level of housekeeping gene \(\beta\)-actin.

Results

Gene expression analysis

The expression pattern of selected immune-related genes associated with the activation of macrophages revealed no significant changes in the transcriptional activities of the tested genes in the duodenum of the vaccinated birds of either line at 3 dpi (data not shown). The expression levels of IL-1\(\beta\), IL-8,

Table 2. Relative fold differences in chicken gene expression in duodenum at 5 and 10 dpi obtained by using the comparative CT method

| Gene   | Average CT | SD  | \(\Delta\text{CT}\) | Fold change \(2^{\Delta\text{CT}}\) |
|--------|------------|-----|-------------------|-----------------------------|
|        |            |     |                   |                             |
| Susceptible line 7: 5 dpi | | | | |
| IFN-\(\alpha\) | 22.50 | 0.15 | 0.15 | 0.90 |
| IFN-\(\gamma\) | 27.56 | 0.10 | 2.17 | 4.49 |
| IL-1\(\beta\) | 24.95 | 0.15 | 2.04 | 4.11 |
| IL-6    | 30.71 | 0.30 | -0.82 | 1.77 |
| IL-8    | 22.29 | 0.25 | -2.53 | 5.77 |
| IL-12   | 31.64 | 0.08 | -0.42 | 1.34 |
| Resistant line 6: 5 dpi | | | | |
| IFN-\(\alpha\) | 24.20 | 0.26 | -1.58 | 2.98 |
| IFN-\(\gamma\) | 29.01 | 0.30 | -1.72 | 3.30 |
| IL-1\(\beta\) | 26.14 | 0.09 | -0.73 | 1.66 |
| IL-6    | 30.94 | 0.23 | -1.16 | 2.24 |
| IL-8    | 23.02 | 0.13 | -1.84 | 3.58 |
| IL-12   | 31.09 | 0.15 | 0.38  | 0.77 |
| Susceptible line 7: 10 dpi | | | | |
| IFN-\(\alpha\) | 23.32 | 0.07 | 0.20  | 0.87 |
| IFN-\(\gamma\) | 26.71 | 0.20 | -2.28 | 4.87 |
| IL-1\(\beta\) | 25.60 | 0.14 | -0.71 | 1.64 |
| IL-6    | 31.57 | 0.19 | 0.34  | 0.79 |
| IL-8    | 23.67 | 0.12 | -1.91 | 3.75 |
| IL-12   | 31.68 | 0.55 | 0.38  | 0.77 |
| Resistant line 6: 10 dpi | | | | |
| IFN-\(\alpha\) | 22.87 | 0.12 | 0.62  | 0.65 |
| IFN-\(\gamma\) | 27.80 | 0.24 | -1.75 | 3.37 |
| IL-1\(\beta\) | 24.27 | 0.06 | -1.14 | 2.20 |
| IL-6    | 30.89 | 0.37 | 0.06  | 0.96 |
| IL-8    | 24.26 | 0.32 | 0.00  | 1.00 |
| IL-12   | 30.07 | 0.39 | 0.81  | 0.57 |

Table 3. Relative fold difference in chicken gene expression in cecal tonsils at 3, 5, and 10 dpi obtained by using the comparative CT method

| Gene   | Average CT | SD  | \(\Delta\text{CT}\) | Fold change \(2^{\Delta\text{CT}}\) |
|--------|------------|-----|-------------------|-----------------------------|
|        |            |     |                   |                             |
| Susceptible line 7: 3 dpi | | | | |
| IFN-\(\alpha\) | 21.64 | 0.04 | -0.36 | 1.28 |
| IFN-\(\gamma\) | 25.71 | 0.04 | -1.78 | 3.43 |
| IL-1\(\beta\) | 23.34 | 0.12 | -0.59 | 1.51 |
| IL-6    | 30.50 | 0.18 | -0.52 | 1.43 |
| IL-8    | 21.87 | 0.08 | -1.86 | 3.62 |
| IL-12   | 24.97 | 0.56 | -0.55 | 1.46 |
| Resistant line 6: 3 dpi | | | | |
| IFN-\(\alpha\) | 21.76 | 0.09 | 0.97  | 0.51 |
| IFN-\(\gamma\) | 24.85 | 0.29 | -2.38 | 5.21 |
| IL-1\(\beta\) | 22.71 | 0.06 | -1.42 | 2.68 |
| IL-6    | 31.07 | 0.11 | -0.44 | 1.36 |
| IL-8    | 22.41 | 0.07 | -1.92 | 3.79 |
| IL-12   | 25.04 | 0.38 | -0.57 | 1.48 |
| Susceptible line 7: 5 dpi | | | | |
| IFN-\(\alpha\) | 21.33 | 0.06 | 0.45  | 0.73 |
| IFN-\(\gamma\) | 21.67 | 0.15 | -5.29 | 39.10 |
| IL-1\(\beta\) | 21.85 | 0.18 | -1.12 | 2.18 |
| IL-6    | 27.31 | 0.30 | 0.71  | 0.61 |
| IL-8    | 22.25 | 0.18 | -1.20 | 2.30 |
| IL-12   | 24.97 | 0.15 | -4.72 | 26.34 |
| Resistant line 6: 5 dpi | | | | |
| IFN-\(\alpha\) | 22.02 | 0.06 | 0.71  | 0.61 |
| IFN-\(\gamma\) | 23.99 | 0.12 | -3.34 | 10.11 |
| IL-1\(\beta\) | 23.01 | 0.86 | -1.26 | 2.39 |
| IL-6    | 30.78 | 0.10 | 0.86  | 0.55 |
| IL-8    | 23.46 | 0.09 | -0.78 | 1.72 |
| IL-12   | 24.88 | 0.20 | -0.90 | 1.86 |
| Susceptible line 7: 10 dpi | | | | |
| IFN-\(\alpha\) | 21.35 | 0.10 | 0.27  | 0.83 |
| IFN-\(\gamma\) | 24.92 | 0.11 | -1.22 | 2.33 |
| IL-1\(\beta\) | 22.83 | 0.04 | 0.32  | 0.80 |
| IL-6    | 30.33 | 0.16 | 0.81  | 0.57 |
| IL-8    | 23.17 | 0.66 | -1.33 | 2.51 |
| IL-12   | 25.08 | 0.20 | -2.22 | 4.66 |
| Resistant line 6: 10 dpi | | | | |
| IFN-\(\alpha\) | 21.09 | 0.18 | 0.71  | 0.61 |
| IFN-\(\gamma\) | 25.82 | 0.05 | -1.84 | 3.58 |
| IL-1\(\beta\) | 22.76 | 0.09 | -1.18 | 2.26 |
| IL-6    | 29.28 | 0.57 | -0.42 | 1.34 |
| IL-8    | 22.68 | 0.11 | -0.46 | 1.38 |
| IL-12   | 24.78 | 0.13 | -0.61 | 1.53 |

Treatment was vaccination with CVI988. dpi, days post-immunization; IFN, interferon; IL, interleukin.
Immune responses to Marek’s disease vaccine

and IFN-γ were upregulated in the duodenum of the vaccinated birds of MD-susceptible line 72 at 5 dpi (Table 2). In addition to IL-1β, IL-8, and IFN-γ, there was increase in the expression level of IFN-α in the duodenum of vaccinated birds of MD-resistant line 63 (Table 2). High transcriptional activity of IFN-γ was detected in the duodenum of birds of both vaccinated lines at 10 dpi (Table 2). IL-8 expression was extended to 10 dpi in the duodenum of vaccinated birds of susceptible line 72 (Table 2). In contrast to duodenum results, IL-8 and IFN-γ were both upregulated in the CT of both vaccinated lines at 3 dpi (Table 3). Additionally, compared to susceptible line 72, IL-1β showed higher transcriptional activity in the CT of vaccinated birds of resistant line 63 at 3 dpi (Table 3). Notably high expression of some of the tested genes was observed in the CT of vaccinated birds at 5 dpi (Table 3). The expression level of IFN-γ was almost 40-fold higher in the vaccinated birds of susceptible line 72 than in the unvaccinated control birds. IL-12 expression was over 26-fold higher in vaccinated susceptible line 72 birds than in the unvaccinated control birds (Table 3). The expression level of IFN-γ was 10-fold higher in the CT of vaccinated resistant line 63 birds than in the age-matched controls at the same sampling time (Table 3). Overexpression of IFN-γ and IL-12 was extended to 10 dpi in the CT of the vaccinated birds of susceptible line 72 (Table 3). Upregulation of IFN-γ was also detected in the CT of the vaccinated birds of resistant line 63 at 10 dpi (Table 3).

Gene expression analysis of isolated spleen macrophages revealed differential expression patterns between the vaccinated birds of the MD-resistant and MD-susceptible lines at 3 and 5 dpi. IFN-α was the only gene with higher expression level in the spleen macrophages of the susceptible line birds at 3 dpi (Table 4). No significant changes were observed in the expression levels of other tested genes in the spleen macrophages of vaccinated birds of susceptible line 72 at 3 or 5 dpi (Table 4). Substantially higher expression levels of IFN-γ (41-fold change), IL-6 (19-fold change), IL-8 (9-fold change), and IL-12 (166-fold change) were observed in the spleen macrophages of the vaccinated resistant line 63 birds at 3 dpi (Table 4). To a lesser extent, similar patterns of upregulation were detected in most of the tested genes in the resistant line 63 birds at 5 dpi (Table 4).

To help visualize the expression patterns of the tested genes in different tissues at different times post-vaccination, the fold changes were converted into bar graphs, as shown in Figs. 1–3 (duodenum, CT, and spleen macrophages, respectively).

**Table 4.** Relative fold difference in chicken gene expression in the spleen macrophages at 3 and 5 dpi obtained by using the comparative C<sub>T</sub> method

| Gene     | Average C<sub>T</sub> | SD | ΔC<sub>T</sub> | Fold change<sup>2<sub>ΔC<sub>T</sub></sub></sup> |
|----------|------------------------|----|---------------|-------------------------------------|
| Susceptible line 72: 3 dpi | | | | |
| IFN-α    | 24.56                  | 0.03 | -3.11        | 8.66                                |
| IFN-γ    | 27.90                  | 0.30 | 0.14         | 0.91                                |
| IL-1β    | 21.33                  | 0.19 | -0.34        | 1.27                                |
| IL-6     | 25.47                  | 0.30 | -0.90        | 1.87                                |
| IL-8     | 28.44                  | 0.15 | -0.32        | 1.25                                |
| IL-12    | 31.88                  | 1.59 | -0.64        | 1.56                                |
| Resistant line 63: 3 dpi | | | | |
| IFN-α    | 25.43                  | 0.86 | 0.45         | 0.73                                |
| IFN-γ    | 24.31                  | 3.02 | -5.36        | 40.96                               |
| IL-1β    | 22.06                  | 0.21 | -0.20        | 1.15                                |
| IL-6     | 22.65                  | 0.65 | -4.25        | 18.99                               |
| IL-8     | 25.42                  | 3.74 | -3.15        | 8.90                                |
| IL-12    | 24.68                  | 2.97 | -7.38        | 166.08                              |
| Susceptible line 72: 5 dpi | | | | |
| IFN-α    | 24.57                  | 0.71 | 2.64         | 0.16                                |
| IFN-γ    | 25.54                  | 0.22 | -0.70        | 1.62                                |
| IL-1β    | 21.79                  | 0.08 | 2.40         | 0.19                                |
| IL-6     | 24.95                  | 0.15 | 1.22         | 0.43                                |
| IL-8     | 28.37                  | 0.31 | 0.84         | 0.56                                |
| IL-12    | 29.69                  | 0.22 | -0.86        | 1.82                                |
| Resistant line 63: 5 dpi | | | | |
| IFN-α    | 25.46                  | 0.12 | 0.79         | 0.58                                |
| IFN-γ    | 26.93                  | 0.03 | -1.00        | 2.00                                |
| IL-1β    | 19.94                  | 0.07 | -1.63        | 3.09                                |
| IL-6     | 24.74                  | 0.01 | -1.40        | 2.63                                |
| IL-8     | 28.06                  | 0.13 | -0.08        | 1.06                                |
| IL-12    | 28.37                  | 0.12 | -1.86        | 3.64                                |

Treatment was vaccination with CVI988. dpi, days post-immunization; IFN, interferon; IL, interleukin.

**Immunohistochemistry**

Although no specific software was used in determining
accurate cell population estimates within the tested tissues, immunohistochemical analysis of CD3⁺ T cells revealed no visible population increase in the duodenum of the vaccinated birds at 5 dpi (panels B and D in Fig. 4; lines 6 and 7, respectively) when compared to the corresponding age-matched control birds (panels A and C in Fig. 4; lines 6 and 7, respectively). Macrophage populations, on the other hand, clearly increased in the duodenum of both the MD-resistant and MD-susceptible lines at 5 dpi (panels F and H in Fig. 4; lines 6 and 7, respectively) when compared to the non-vaccinated control birds (panels E and G in Fig. 4; lines 6 and 7, respectively).

We used anti-gB monoclonal (glycoprotein of CVI988) antibody to detect the presence of virus particles within the CT

Fig. 2. Bar graphs showing the expression patterns of the tested genes within the cecal tonsils of both Marek’s disease lines at 3, 5, and 10 days post-immunization (dpi). For a statistical analysis summary, please see Table 3. IFN, interferon; IL, interleukin.

Fig. 3. Bar graphs showing the expression patterns of the tested genes in spleen macrophages of both Marek’s disease lines at 3 and 5 days post-immunization (dpi). For a statistical analysis summary, please see Table 4. IFN, interferon; IL, interleukin.

Fig. 4. Images from the immunohistochemical analysis of CD3⁺ T cells and macrophage populations within the duodenum of control and vaccinated birds of the resistant and susceptible Marek’s disease lines at 5 days post-immunization. The tissue samples were incubated with combination of mouse anti-chicken CD3⁺ T cells or macrophage monoclonal antibodies (primary) and biotinylated horse anti-mouse IgG (secondary) for detection of specific immune cells. Panels B and D show the CD3⁺ T cell populations within the duodenum of vaccinated birds of the resistant and susceptible lines, respectively, while panels A and C present the corresponding control tissues. Panels F and H show the macrophage populations within the duodenum of vaccinated birds of the resistant and susceptible lines, respectively, while panels E and G show the corresponding non-vaccinated control tissues. Scale bars = 200 µm (A-D), 20 µm (E-H).
Immune responses to Marek’s disease vaccine

www.vetsci.org

Fig. 5. Images from the immunohistochemical analysis of CVI988/Rispens antigen gB within the duodenum and the cecal tonsil (CT) of the vaccinated birds of the resistant and susceptible lines at 5 days post-immunization. The tissue samples were incubated with combination of mouse anti-gB monoclonal antibody (primary) and biotinylated horse anti-mouse IgG for detection CVI988 virions. Panels B and D show the duodenum and CT tissues of birds of vaccinated resistant line 63, respectively, stained with the anti-gB of CVI988/Rispens, while panels A and C, respectively, are the corresponding non-vaccinated control tissues. The gB antigen of CVI988/Rispens is depicted within duodenum and the CT of the vaccinated birds of the susceptible line 72 in panels F and H, respectively, while the corresponding control tissues are represented in panels E and G, respectively. Scale bars = 200 μm (A–H).

and duodenum of the vaccinated birds. No virus-specific antigen was detected in the duodenum or CT of the vaccinated birds of resistant line 63 at 5 dpi (panels B and D in Fig. 5, respectively). The corresponding control birds were also negative for the virus antigen (panels A and C in Fig. 5, respectively). However, there was a significant number of virus particles present in the duodenum and CT of the vaccinated birds of susceptible line 72 (panels F and H in Fig. 5, respectively). Panels E and G in Fig. 5 present the corresponding duodenum and CT tissue results, respectively, for the negative birds.

Discussion

MDV, the etiologic agent of MD, is an alpha-herpesvirus that causes various clinical symptoms including anemia, weight loss, transient paralysis, bursal/thymic atrophy, T cell lymphomas, and immunosuppression [4,10,15]. Although MD has been controlled by vaccination since the 1970s [6], the underlying mechanism behind its protection is unclear. Unlike most animal and human vaccines that require activation and direct involvement of adaptive immune system for proper protection, MD vaccines induce partial protection as early as 24 to 48 h post-vaccination [20]. Depending on the protective efficacy of the vaccine used, the immunity provided can attain 95% to 100% by day 5 post-vaccination [20].

The focus of this study was to investigate the effect of vaccination on the activation of macrophages within spleen, CT, and duodenum tissues of MD-susceptible and MD-resistant chicken lines by analyzing the expression patterns of selected immune-related genes associated with activation of macrophages. Additionally, we used immunohistochemical analysis to evaluate the populations of CD3+ T cells and macrophages in the tissues of control and vaccinated birds at day 5 post-vaccination. The results obtained from our gene expression analysis revealed no significant changes in the expression patterns of tested genes at 3 dpi in the duodenum of either MD line. At 5 dpi, however, IFN-γ, IL-1β, and IL-8 were upregulated in the duodenum of birds of MD-susceptible line 72, IFN-α, IFN-γ, IL-6, and IL-8 showed higher transcriptional activities in the duodenum of the vaccinated birds of MD-resistant line 63 when compared to the age-matched control birds (Table 2). At day 10 post-vaccination, the expressions of IFN-γ and IL-8 were higher in the duodenum of susceptible line 72 than in the age-matched control birds. IFN-γ was also upregulated in the duodenum of the vaccinated birds of resistant line 63. It is safe to assume that, at day 10 post-vaccination, the adaptive immune system is activated and, consequently, T and possibly B cells are contributing to the increased expression of some of the tested genes. It should also be pointed out that NK cells, being one of the major cellular components of the innate immune system, are likely involved in vaccine-mediated
protection [34]. Killing of virus-infected and tumor cells in a non-major histocompatibility complex-restricted manner is mediated by exocytosis of granules and release of perforin and granzymes and production of IFN-γ, which leads to apoptosis of target cells and has a direct effect on the outcome of adaptive immune responses [5,9,31,38,41]. Therefore, it is more than likely that NK cells also contribute to the upregulation of IFN-γ in the tested tissues of the vaccinated birds.

Unlike duodenum, upregulation of IFN-γ and IL-8 was detected in the CT of both chicken lines at 3 dpi. In addition, IL-1β showed high transcriptional activity in the CT of resistant line 63 birds (Table 3). The highest levels of expression of the tested genes were in the CT of the vaccinated birds at day 5 post-vaccination. IFN-γ and IL-12 were significantly upregulated in the CT of the vaccinated birds of susceptible line 72 when compared to the unvaccinated control birds (39- and 26-fold increases, respectively). The expression level of IFN-γ in the CT of resistant line 63 birds was also considerably higher than that of the control birds (10-fold increase; Table 3). Once again, the high expressions of some of the tested genes were extended to day 10 post-vaccination, which could be partially due to the activation and contribution of the adaptive immune system (Table 3).

IFN-α was the only gene with a higher expression level in the isolated spleen macrophages of vaccinated susceptible line 72 birds than that of resistant line 63 birds at day 3 post-vaccination (9-fold increase). In contrast, IFN-γ (41-fold increase), IL-6 (19-fold increase), IL-8 (9-fold increase), and IL-12 (166-fold increase) exhibited the highest levels of expression in the spleen macrophages of resistant line 63 birds at day 3 post-vaccination. Similar patterns of expression, but with smaller fold changes, were observed for IFN-γ, IL-1β, IL-6 and IL-12 in the spleen macrophages of the vaccinated birds of resistant line 63 at 5 dpi (Table 4). The overall gene expression pattern in the tested tissues of both chicken lines are depicted in Figs. 1 to 3 as bar graphs for improved visualization (duodenum, CT, and spleen macrophages, respectively).

To test the possibility of activation and contribution of the adaptive immune system in the upregulation of tested genes, we undertook immunohistochemical analysis to evaluate the population of CD3+ T cells in the duodenum of control and vaccinated birds of both MD lines at 5 dpi. The results revealed no detectable increases in the populations of T cells within the duodenum of the vaccinated birds of either line when compared to the age- and line-matched control birds (panels A–D in Fig. 4). Immunohistochemical analysis of macrophages, however, showed a significant increase in the population of the phagocytic cells within the duodenum of vaccinated birds of both lines at 5 dpi (panels E–H in Fig. 4). There was insufficient CT tissue available to test the populations of CD3+ T cells or macrophages at either 3 or 5 dpi.

Immunohistochemical analysis detected no CVI988/Rispens antigen within the CT or duodenum of the vaccinated birds of the resistant line at 5 dpi. A substantial number of virus particles, however, were detected within the CT and duodenum of the MD-susceptible line (Fig. 5). It is possible that the inhibitory effect of the vaccine virus on macrophage function in the susceptible line 72 birds resulted in a lack of activation of NK cells and elimination of virus particles. The absence of any detectable CVI988/ Rispens antigens within the tested tissues of the resistant line 63 birds is probably an indication that the virus was unable to break the macrophage barrier, resulting in activation of NK cells and, ultimately, clearance of the viral infection.

Macrophages and NK cells of the innate immune system play critical roles in vaccine-mediated protection against pathogenic strains of MDV. This study sheds light on the possible role of the innate immune system in vaccine-mediated protection and points the way for future development of a recombinant vaccine that specifically modulates innate immune responses.

Acknowledgments

The authors would like to thank Jennifer Pierluissi for excellent technical assistance.

Conflict of Interest

The authors declare no conflicts of interest.

References

1. Arango Duque G, Descoteaux A. Macrophage cytokines: involvement in immunity and infectious diseases. Front Immunol 2014, 5, 491.
2. Bacon LD, Hunt HD, Cheng IH. A review of the development of chicken lines to resolve genes determining resistance to diseases. Poult Sci 2000, 79, 1082-1093.
3. Baigent S, Davison T. Marek’s disease virus: biology and life cycle. In: Davison F, Nair V (eds.). Marek’s Disease: An Evolving Problem. pp. 62-77, Elsevier Academic Press, Oxford, 2004.
4. Biggs PM. The Leeuwenhoek Lecture, 1997. Marek's disease herpesvirus: oncogenesis and prevention. Philos Trans R Soc Lond B Biol Sci 1997, 352, 1951-1962.
5. Biron CA. Initial and innate responses to viral infections—pattern setting in immunity or disease. Curr Opin Microbiol 1999, 2, 374-381.
6. Blaxland JD, Macleod AJ, Hall T. Trials with Marek's disease vaccines prepared from a turkey herpes virus and an attenuated Marek's disease virus. Vet Rec 1975, 97, 50-52.
7. Calnek BW. Pathogenesis of Marek's disease virus infection. Curr Top Microbiol Immunol 2001, 255, 25-55.
8. Calnek BW, Addlinger HK, Kahn DE. Feather follicle epithelium: a source of enveloped and infectious cell-free herpesvirus from Marek's disease. Avian Dis 1970, 14, 219-233.
9. Cerwenka A, Lanier LL. Natural killer cells, viruses and cancer. Nat Rev Immunol 2001, 1, 41-49.
10. Churchill AE, Biggs PM. Agent of Marek's disease in tissue culture. Nature 1967, 215, 528-530.
11. Davison F, Nair V. Marek's Disease: An Evolving Problem. Elsevier Press, The Netherlands and Boston, 2004.
12. de Boer GF, Groenendaal JE, Boerrigter HM, Kok GL, Pol JM. Protective efficacy of Marek's disease virus (MDV) CVI-988 CEF65 clone C against challenge infection with three very virulent MDV strains. Avian Dis 1986, 30, 276-283.
13. Djeraba A, Bernardet N, Dambrine G, Quéré P. Nitric oxide inhibits Marek's disease virus replication but is not the single decisive factor in interferon-gamma-mediated viral inhibition. Virology 2000, 277, 58-65.
14. Haffer K, Sevoian M, Wilder M. The role of the macrophages in Marek's disease: in vitro and in vivo studies. Int J Cancer 1979, 23, 648-656.
15. Jarosinski KW, Tischer BK, Trapp S, Osterrieder N. Marek's disease virus: lytic replication, oncogenesis and control. Expert Rev Vaccines 2006, 5, 761-772.
16. Kodama H, Mikani T, Inoue M, Izawa H. Inhibitory effects of macrophages against Marek's disease virus plaque formation in chicken kidney cell cultures. J Natl Cancer Inst 1979, 63, 1267-1271.
17. Lanier LL. Evolutionary struggles between NK cells and viruses. Nat Rev Immunol 2008, 8, 259-268.
18. Lanier LL. Up on the tightrope: natural killer cell activation and inhibition. Nat Immunol 2008, 9, 495-502.
19. Lee LF, Liu X, Witter RL. Monoclonal antibodies with specificity for three different serotypes of Marek's disease viruses in chickens. J Immunol 1983, 130, 1003-1006.
20. Lee LF, Zhang H, Heidari M, Lupiani B, Reddy SM. Evaluation of factors affecting vaccine efficacy of recombinant Marek's disease virus lacking the Meq oncogene in chickens. Avian Dis 2011, 55, 172-179.
21. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2^-ΔΔCt method. Methods 2001, 25, 402-408.
22. Markowskis-Grimsnud CJ, Schat KA. Cytotoxic T lymphocyte responses to Marek's disease herpesvirus-encoded glycoproteins. Vet Immunol Immunopathol 2002, 90, 133-144.
23. Mast J, Goddeeris BM. Development of immunocompetence of broiler chickens. Vet Immunol Immunopathol 1999, 70, 245-256.
24. Mast J, Goddeeris BM, Peeters K, Vandesande F, Berghman LR. Characterisation of chicken monocytes, macrophages and interdigitating cells by the monoclonal antibody KUL01. Vet Immunol Immunopathol 1998, 61, 343-357.
25. Matkina S, Paaneman A, Miettinen M, Kurimoto M, Timonen T, Jukunen I, Sareneva T. IFN-α and IL-18 synergistically enhance IFN-γ production in human NK cells: differential regulation of Stat4 activation and IFN-γ gene expression by IFN-α and IL-12. Eur J Immunol 2001, 31, 2236-2245.
26. Okazaki W, Purchase HG, Burmester BR. Protection against Marek's disease by vaccination with a herpesvirus of turkeys. Avian Dis 1970, 14, 413-429.
27. Powell PC, Hartley KJ, Mustill BM, Rennie M. Studies on the role of macrophages in Marek's disease of the chicken. J Reticuloendothel Soc 1983, 34, 289-297.
28. Qureshi MA. Avian macrophage and immune response: an overview. Poult Sci 2003, 82, 691-698.
29. Rispens BH, van Vloten H, Mastenbroek N, Maas JL, Schat KA. Control of Marek's disease in the Netherlands. Isolation of an avirulent Marek's disease virus (strain CVI 988) and its use in laboratory vaccination trials. Avian Dis 1972, 16, 108-125.
30. Rispens BH, van Vloten H, Mastenbroek N, Maas JL, Schat KA. Control of Marek's disease in the Netherlands. II. Field trials on vaccination with an avirulent strain (CVI 988) of Marek's disease virus. Avian Dis 1972, 16, 126-138.
31. Russell JH, Ley TJ. Lymphocyte-mediated cytotoxicity. Annu Rev Immunol 2002, 20, 323-370.
32. Schat K, Nair V. Marek's disease. In: Saif YM, Fadly AM, Glisson JR, Mc Dougald LB, Nolan LK, Swayne DE (eds.). Diseases of Poultry. pp. 452-514, Iowa State University Press, Ames, 2008.
33. Schat KA, Calnek BW. Characterization of an apparently nononcogenic Marek's disease virus. J Natl Cancer Inst 1978, 60, 1075-1082.
34. Sharma JM. Natural killer cell activity in chickens exposed to Marek's disease virus: inhibition of activity in susceptible chickens and enhancement of activity in resistant and vaccinated chickens. Avian Dis 1981, 25, 882-893.
35. Van Immerseel F, De Buck J, De Smet I, Mast J, Haesebruck F, Ducatelle R. The effect of vaccination with a Salmonella Enteritidis araA mutant on early cellular responses in caecal lamina propria of newly-hatched chickens. Vaccine 2002, 20, 3034-3041.
36. Venugopal K. Marek's disease: an update on oncogenic mechanisms and control. Res Vet Sci 2000, 69, 17-23.
37. VonBülow V, Weiler H, Klaes A. Activating effects of interferons, lymphokines and viruses on cultured chicken macrophages. Avian Pathol 1984, 13, 621-637.
38. White DW, Keppel CR, Schneider SE, Reese TA, Coder J, Payton JE, Ley TJ, Virgin HW, Fehniger TA. Latent herpesvirus infection arms NK cells. Blood 2010, 115, 4377-4383.
39. Xing Z, Schat KA. Inhibitory effects of nitric oxide and gamma interferon on in vitro and in vivo replication of Marek's disease virus. J Virol 2000, 74, 3605-3612.
40. Xu M, Fitzgerald SD, Zhang H, Karcher DM, Heidari M. Very virulent plus strains of MDV induce an acute form of transient paralysis in both susceptible and resistant chicken lines. Viral Immunol 2012, 25, 306-323.
41. Yokoyama WM, Kim S, French AR. The dynamic life of natural killer cells. Annu Rev Immunol 2004, 22, 405-429.